Exploring the Impact of Montelukast, SPM, and/or Almond/Almond Oil Supplementation on Lipid Mediator Biosynthesis in Colorectal, Sarcomas, Brain Tumors, Endometrial, and Ovarian Cancer: A Pilot Study
University of South Florida
Summary
The purpose of this study is to create a prospective investigation to examine the effects of montelukast, almonds/almond oil, and specialized pro-resolving mediators (SPMs) on lipid profiles and tumor-associated macrophages (TAMs) in cancer patients (colorectal cancer, sarcoma, brain tumors, endometrial cancer, and ovarian cancer). The focus will be on assessing changes in lipid mediator concentrations, TAM reprogramming, and immune cell function in treated versus untreated patients. It is hypothesized that montelukast will reduce the pro-inflammatory effects of leukotriene B4 (LTB4), while SPMs and almonds/almond oil will shift the balance toward pro-resolving mediators, enhancing anti-inflammatory and immune-stimulatory responses and reprogramming TAMs.
Description
This prospective study investigates the effects of montelukast, almonds/almond oil, and specialized pro-resolving mediators (SPMs) on lipid profiles and tumor-associated macrophages (TAMs) in patients with colorectal cancer (CRC), sarcoma, brain tumors (BT), endometrial cancer (EC), and ovarian cancer (OvCa). Patients receiving these treatments will be compared to untreated controls, with tissue samples collected post-surgery for analysis. A cohort of patients who have undergone tumor resection will be included for the assessment of lipid mediator concentrations (approximately 65 arachidonic a…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Newly diagnosed individuals with stages I-IV colorectal or ovarian cancer, grade 1 and 2 endometrial cancer, as well as those with brain tumors or sarcoma. 2. Participants scheduled for surgical intervention at least two (2) weeks from the day of enrollment. 3. Patients must be able to understand and willing to sign a written informed consent document for both this study and the University of South Florida (USF)/ Tampa General Hospital (TGH) Biorepository study (STUDY000356). 4. Age 18 or older. Exclusion Criteria: 1. Inability to give consent due to a mental conditio…
Interventions
- OtherNo Interventions
No study treatment other than the standard of care management.
- Dietary SupplementSports Pro Resolve 4 g
Sports Pro Resolve 4 tabs (2 g) twice daily
- Dietary SupplementDouble Wood SPM 4 g
Double Wood SPM 4 tabs (2 g) twice daily
- Dietary Supplement20 California Sweet Almonds
10 California Sweet Almonds twice daily
- DrugMontelukast 10 Mg Oral Tablet
Montelukast 10 Mg Oral Tablet daily
- Combination ProductMontelukast 10 Mg Oral Tablet and SPM 4 g
Montelukast 10 Mg Oral Tablet and SPM 4 g
Locations (2)
- Tampa General HospitalTampa, Florida
- University of South FloridaTampa, Florida